Cambridge Healthtech Institute's 3rd Annual
Safety and Efficacy of Bispecific Antibodies, ADCs, and Combination Therapies
Enhancing Safety and Creating Synergies with Novel Therapeutic Modalities
11 November 2025 ALL TIMES WET (GMT/UTC)
Novel bispecific and multispecific antibodies, antibody-drug conjugates (ADCs), and combination treatments open the door to addressing a broader set of clinical indications. Alongside these developments come new challenges in optimizing safety and efficacy of these next-generation therapeutics. At PEGS Europe, Cambridge Healthtech Institute’s Third Annual Safety and Efficacy of Bispecific Antibodies, ADCs, and Combination Therapies program will highlight novel therapeutic candidates and how researchers are mitigating toxicity, managing combination therapies, reducing off-target effects, and addressing challenges in treatment of solid tumors. This meeting will complement topics in bispecific antibody discovery and engineering for meeting unmet clinical needs.
Recommended Short Course*
Monday, 4 November, 14:00 – 17:00
SC3: Developability of Bispecific Antibodies
*Separate registration required. See short courses page for details. All short courses take place in-person only.